Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results. The general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrated contribution of several genomic markers (Genome Wide Association study, GWAs), new clinical and analytical variables (human exposome concept) and gender perspective to the prediction of response to the intervention at 12 month and its long-term longitudinal maintenance (3 years). The investigators intend, therefore, to provide new evidence to advance towards precision medicine. The investigators will focus our attention also on identifying those patients who, after being classified at the weight loss nadir as responders experienced weight regain.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Men and women between the ages of 18 and 65 at the time of surgery

• SG or RYBP as bariatric procedure.

• With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI\>40.0 kg/m2 at the time of surgery.

• Provision of an informed consent form signed and personally dated by the patient.

• With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).

Locations
Other Locations
Spain
IRBLleida
RECRUITING
Lleida
Contact Information
Primary
Albert Lecube Torelló, PhD
alecube@gmail.com
0034973705183
Backup
Eva López
elopez@irblleida.cat
0034973706636
Time Frame
Start Date: 2024-03-15
Estimated Completion Date: 2028-11-29
Participants
Target number of participants: 6966
Treatments
Lleida
Saliva sample collection and questionnaire
Barcelona
Saliva sample collection and questionnaire
Madrid
Saliva sample collection and questionnaire
Málaga
Saliva sample collection and questionnaire
Santiago de Compostela
Saliva sample collection and questionnaire
Pamplona
Saliva sample collection and questionnaire
León
Saliva sample collection and questionnaire
A Coruña
Saliva sample collection and questionnaire
Mallorca
Saliva sample collection and questionnaire
Tenerife
Saliva sample collection and questionnaire
Las Palmas
Saliva sample collection and questionnaire
Sponsors
Collaborators: ISCIII
Leads: Institut de Recerca Biomèdica de Lleida

This content was sourced from clinicaltrials.gov